Retina

The device features cross-polarized light technology, allowing for image clarity without the need for pupil dilation.

Understanding the latest innovative technologies.

A research team for the $3.3 million study will assess the front and the back of the eye and different types of glucose dysfunction.

Some cases require unorthodox approaches.

It’s time to act with a few rational and relatively modest proposals.

Comanagement is a key component for treatment of disease.

The new smart glasses utilize artificial intelligence to visually assist those with age-related macular degeneration and other retinal disorders causing vision loss.

Case complexity underscores the importance of interdisciplinary communication.

The study helped identify predisposing factors for severe SANS in astronauts.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Study investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata.

Pediatric TINU syndrome is rare, but responds well to treatment.

According to Genentech, faricimab-svoa is the first and only syringe that is prefilled with an FDA-approved bispecific antibody to treat wet AMD, DME and RVO.

The company also submitted a marketing authorization application with the European Medicines Agency.

Respecting the clinical importance of the pachychoroid spectrum is vital when analyzing OCT scans.

Rafieetary emphasizes the importance of follow-up plans and consistent support to prevent patients from dropping out of treatment, which can negatively impact their prognosis.

Neurotech's ocular implant NT-501 utilizes encapsulated cell therapy to slow the progression of macular telangiectasia type 2 (MacTel). The implant was given a PDUFA goal date of December 17, 2024.

Pathogenesis and detection of diabetic retinopathy.

The study evaluates the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

The French study found that a complete capsular removal seemed to be the safer option for pediatric patients with Marfan syndrome in terms of risk of retinal detachment.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

DF-003 is a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1), an inhibitor believed to be responsible for causing ROSAH syndrome.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene. The gene therapy is being designed as a one-time treatment for life.